The largest database of trusted experimental protocols

Antibody against cd31

Manufactured by BD
Sourced in United States

The Antibody against CD31 is a laboratory reagent used for the detection and identification of the CD31 (Platelet Endothelial Cell Adhesion Molecule) protein. CD31 is a cell surface glycoprotein expressed on the surface of endothelial cells, platelets, and certain immune cells. This antibody can be used in various immunological techniques, such as flow cytometry, immunohistochemistry, and Western blotting, to study the expression and distribution of CD31 in biological samples.

Automatically generated - may contain errors

8 protocols using antibody against cd31

1

Immunofluorescent CD31 Endothelial Marker

Check if the same lab product or an alternative is used in the 5 most similar protocols
Endothelial marker was assessed by immunofluorescence using an antibody against CD31 (BD Biosciences Pharmigen, San Diego, CA, USA). All primary antibodies were revealed with a secondary antibody conjugated anti-mouse IgGs with Alexa Fluor 488 (Invitrogen Molecular Probes, Eugene, OR, USA). Nuclei were stained with dihidrocloreto de 4,6 diamino-2-fenilindol; (DAPI) (Invitrogen Molecular Probes, Eugene, OR, USA).
+ Open protocol
+ Expand
2

Quantifying Muscle Capillary and Arteriole Density

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were anaesthetized, perfused with normal saline and then fixed with 10% phosphate-buffered formalin for 10 min at 100 mm/Hg, via left ventricle. Fixed adductor muscles were paraffin embedded and 5-μm-thick sections were cut from each sample with muscle fibres oriented in the transverse direction. Capillary density was determined by counting the capillary structures in 30-40 random fields using an antibody against CD31 (BD Bioscience). In other sections, arterioles were identified by using an antibody against α-smooth muscle actin (AbCam) and counted. Counts were performed by two readers blinded to the treatment and similar results were obtained. Analyses were performed using a Zeiss LSM 710 confocal microscope. The number of capillaries and arterioles was normalized to the section area calculated with ZEN 2008 software (Carl Zeiss).
+ Open protocol
+ Expand
3

Quantifying Ischemic Muscle Capillaries

Check if the same lab product or an alternative is used in the 5 most similar protocols
Transverse sections of gastrocnemius and soleus muscles of ischemic hind limbs were cut and embedded in Optimal Cutting Temperature Compound for frozen sections. Antibody against CD31 (BD Pharmingen, San Jose, CA) was stained to recognize capillary of ischemic muscles, and 4',6-diamidino-2phenylindole (Thermo Fisher Scienti c, Waltham, MA) was used to recognize nuclei. Fluorescent elds were captured by uorescence microscopy (DP74, Olympus). The capillary number was counted using ImageJ in randomly selected elds for a total of 20 different elds per section and 3 sections per animal. The capillary density was expressed as CD31 positive capillaries per eld.
+ Open protocol
+ Expand
4

Tumor Tissue Analysis of HIF-1α, MMP-2, VEGF, and Ki67

Check if the same lab product or an alternative is used in the 5 most similar protocols
Representative tumor tissues (four from each group) were harvested and fixed in 10% neutral buffered formalin at 4 °C for 12 h. All tissues were paraffin embedded. Sections (5 μm) were micro-waved in citrate buffer and were stained with antibody against HIF-1α (Novus biological, NB100-105), Matrix metalloproteinase-2 (MMP-2) (Abcam, ab86607) and VEGF (Abcam, ab46154) to visualize the protein status. Sections were stained with antibody against Ki67 (Abcam, ab28364) to test the level of cell proliferation. For CD31 staining, sections were permeabilized with 36 μg/ml proteinase K (Roche Diagnostics Corp.) and stained with antibody against CD31 (BD, Bioscience). Direct and indirect tyramide signal amplification kits (NEN Life Science Products, Inc.) were used to amplify staining signals. Sections were photographed at x200 magnification using an Olympus AX70 microscope. Vessel density (average of five fields) was determined with Image-Pro software.
+ Open protocol
+ Expand
5

Fatty Acid Quantification and Antibody Validation

Check if the same lab product or an alternative is used in the 5 most similar protocols
All of the fatty acids, i.e., EETs, EpOMEs and HDHAs were obtained from Cayman Chemicals Europe (Tallinn, Estonia). NADPH was from Applichem (Darmstadt, Germany) and tamoxifen was from Sigma Aldrich (Deisenhofen, Germany). Other chemicals were purchased from Merck (Darmstadt, Germany) or Sigma Aldrich. The anti-Cyp2c44 antibody was generated as described [23 (link)], and the antibody directed against aquaporin 4 (AQP4) was from Santa Cruz (TX, USA), the antibody against CD31 was from BD biosciences (Heidelberg, Germany), the phospho histone 3 antibody was from Merck Millipore (Darmstadt, Germany), and the anti-ETS-related gene (ERG) antibody from Abcam (Cambridge, UK).
+ Open protocol
+ Expand
6

Vascular Reactivity Measurement Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sodium pentobarbital (Nembutal) was obtained from Sanofi (Brussels, Belgium), indomethacin from Federa (Belgium), antibody against CD31 from BD (Erembodegem, Belgium), phenylephrine hydrochloride, acetylcholine-chloride, LNNA, L-NAME, Na2-ATP from Sigma, Fura 2-AM from Molecular Probes (The Netherlands), trinitroglycerin solution (1%, Merck, Belgium), CPA (Tocris Bioscience, United Kingdom).
+ Open protocol
+ Expand
7

Retinal Angiogenesis in Hyperoxia Exposure

Check if the same lab product or an alternative is used in the 5 most similar protocols
The OIR models for the WT and DIXDC1 KO mice were prepared as described previously [59 (link)]. Mice at P7 were exposed to a hyperoxic atmosphere (75% O2) condition for 5 days and returned to normoxic condition for additional 5 days. The mice were anesthetized and sacrificed using avertin. The eyes were removed and fixed in 4% PFA (pH 7.4) for 30 min at RT. The retinae were isolated and incubated in blocking solution for 1 h (all at RT) and incubated overnight with antibody against CD31 (BD Pharmingen) at 4 °C. After 5 washes in PBS containing 1% Triton X-100, the retinae were incubated with Alexa Fluor 594 (Invitrogen, Thermo Scientific) for 3 h at RT. Retinae were then washed with PBS containing 1% Triton X-100 5 times and postfixated with 4% PFA for 5 min. Retinae were then flat mounted on slides using coverslides and mounting solution (Dako, Catalog S3023) and analyzed using a confocal microscope (LSM 880; Carl Zeiss).
+ Open protocol
+ Expand
8

Signaling Pathway Profiling Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies against phospho-p38MAPK (#9211), phospho-ERK1/2 (#9101), phospho-c-Jun
NH2-terminal kinase (JNK; #9251), phospho-AKT (#9271), p38MAPK (#9212), ERK1/2
(#9102), JNK (#9258), AKT (#9272), Mouse IgG Isotype Control (#5415S), and
Normal rabbit IgG (#2729S) were purchased from Cell Signaling (Danvers, MA,
USA). Antibodies against cyclin E (sc-247), cyclin D1 (sc-8396),
cyclin-dependent kinase (CDK)-4 (sc-23896), CDK2 (sc-6248), p27KIP1 (sc-1641),
p53 (sc-126), glyceraldehyde 3-phosphate dehydrogenase (GAPDH, sc-47724), and
p21WAF1 (sc-6246) were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA, USA). Antibodies against VEGFR-2 (#2479), eNOS (#2479), phospho-VEGFR-2
(#4991), and phospho-eNOS (S1177) were purchased from Cell Signaling. Antibodies
against MMP-2 (#AB19167) and MMP-9 (#04-1150) were obtained from Millipore
(Massachusetts, USA). Human recombinant VEGF (293-VE) was purchased from R&D
Systems (Minneapolis, USA). LY294002, SB203580, SP600125, and U0126 were
obtained from Calbiochem (San Diego, CA, USA). The nuclear extraction kit and
electrophoretic mobility shift assay (EMSA) kit (AY1XXX)
were purchased from Panomics (Fremont, USA). Antibody against CD31 was obtained
from BD PharMingen (San Diego, CA, USA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!